에 대한 최신 뉴스 B2Gold (AMEX:BTG) 주식

B2Gold

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Macro,View,Of,Stacks,Of,Gold,Bars

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AAAU

CGAU

Market Vectors ETF Trust Market Vectors Gold Miners

GLDM

GOLD

PAAS

RGLD

SSRM

TFPM

월요일(21일) 금 가격이 사상 최고치로 급등했다. 금은 월요일 오전 11시 20분(동부표준시 기준) 온스당 2.5% 상승한 3,410달러로 상승했다. 이는 미국 금융자산에 대한 불신과 인플레이션 우려로 인해 2010년대 초 글로벌 부채 위기 이후 볼 수 없었던 안전자산으로의 도피가 이어지는 것을 의미한다.

금 가격 사상 최고치, 2011년 이후 가장 강력한 2개월 랠리···엄청난 금 ETF 매수세도 주목

What Happened

Equities

Mid Cap

GDXJ

금 가격의 강력한 상승세가 계속되고 있다. 목요일 금이 새로운 최고가를 경신한 것은 투자자들이 증가하는 무역 긴장과 경제적 불확실성으로부터 포트폴리오를 보호하려고 서두른 결과이다.
 SPDR 골드 트러스트(NYSE:GLD)가 추적하는 금 현물 가격은 동부 표준시 기준 오후 1시 55분에 온스당 2,979.76달러로 거래되었으며, 이는 1.6% 상승한 것으로, 세 번째 연속 상승세를 기록했다. 금속은 2025년까지 14% 급등하여 모든 주요 자산 클래스보다 높은 상승률을 보였다.

무역전쟁 우려가 안전자산 수요를 촉진하며 금 가격이 사상 최고치 기록: 광산주 급등

B2Gold Corp

Bitcoin Gold - United States Dollar

STKd 100% Bitcoin & 100% Gold ETF

Bitcoin Group SE

Bigtincan Holdings Ltd

BITCOIN GENERATION INC by Bitcoin Generation Inc.

Bitcoin Generation Inc

BT Group PLC

BTS GRP HLDGS PUB CO by BTS Group Holdings Public Company Ltd

BTS Group Holdings PLC

BTS GRP HLDGS PUB NVDR by BTS Group Holdings Public Company Ltd

BTG PLC SP/ADR by BTG plc

Personalized medicine, which involves tailoring treatment to a patient&#8217;s unique disease profile, is widely regarded as the holy grail of medicine. However, the current implementation of this approach faces significant hurdles.
Bank of America Securities (BofA) highlights that the precision medicine approach is currently <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">cost, labor, and time-intensive</a>.
Analysts Alec Stranahan and Michael Ryskin specifically point out that the substantial amount of manual work involved in processing complex biological data and making treatment decisions leads to considerable delays.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Beyond the practical challenges, precision medicine also grapples with data validation issues. Given the infinitely complex nature of biology and the huge number of interactions between biological systems, researchers often run into issues with validating the impact of genes/pathways associated with disease progression/response to treatment.
Despite these inherent challenges, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is widely recognized as a pivotal enabler for advancing precision medicine.
Consequently, a number of companies are actively leveraging these technologies to innovate within the precision medicine landscape, striving to make tailored treatments more accessible, efficient, and effective.
These companies include Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), Quest Diagnostics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), and LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), each employing AI in unique ways to enhance diagnostics, therapy selection, and overall patient care across the care continuum.
<h2 class="wp-block-heading">Tempus AI</h2>
BofA analyst says Tempus AI perfectly fits the theme of <a target="_blank" href="https://www.benzinga.com/news/movers-shakers/25/06/45726456/tempus-ai-stock-is-surging-today-what-investors-are-watching" rel="noreferrer noopener">AI in precision medicine</a>.
Like most MDx companies, Tempus AI has built its business off an industry-leading database of clinico-genomic data. Tempus leverages this data by training AI/ML algorithms to parse through the data and detect patterns and anomalies.&nbsp;&nbsp;
BofA reiterates a Neutral rating for Tempus AI, given its already premium valuation. The analyst remains constructive on the business and key markets. However, due to peer group expansion, BofA raised its price <a target="_blank" href="https://www.benzinga.com/quote/TEM/analyst-ratings" rel="noreferrer noopener">forecast from $68 to $70</a>.
<h2 class="wp-block-heading">Guardant Health</h2>
Guardant Health was an early mover in the liquid biopsy cancer testing/therapy selection market with their <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Guardant 360 (G360) test</a>.
Guardant Health has a clear goal to build upon its G360 test (therapy selection) and expand across the care continuum, thus allowing it to participate in a patient&#8217;s receiving precision medicine at all stages post-cancer diagnosis.
Guardant Health has its business built on the algorithms that it runs.
BofA <a target="_blank" href="https://www.benzinga.com/quote/GH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on Guardant Health, given its leading position, strong growth profile, and upcoming catalyst path for new products.
<h2 class="wp-block-heading">Exact Sciences</h2>
BofA analysts say Exact Sciences Corp. has expanded to offer services <a href="https://www.benzinga.com/general/health-care/25/05/45165534/cancer-diagnostic-firm-exact-sciences-ceo-says-strong-q1-paves-way-for-transformative-2025-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">across the care continuum</a>.
While Exact Sciences started screening for colorectal cancer specifically, their focus has been steered towards all indications and across the treatment paradigm.
Exact Sciences&#8217; legacy Cologuard test / early detection doesn&#8217;t necessarily &#8220;fit&#8221; the precision medicine theme; however, everything Exact has done since is &#8220;precision medicine / AI-aligned,&#8221; BofA added in its investor note on Wednesday.
Given its strong financial profile and near-term catalyst path, the analyst maintains a <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Buy rating on Exact Sciences</a>.
<h2 class="wp-block-heading">NeoGenomics</h2>
NeoGenomics has been known as a traditional reference lab offering many hotspot tests. However, by adding the PanTracer testing family and data services offering, NeoGenomics leverages the numerous hotspot data points and can build those into a more robust AI algorithm to inform the more modern therapy selection tests.
The dataset/algorithm and 500+ tests create a flywheel where the tests that are sold generate information. The information informs the algorithm, eventually leading to more accurate algorithms, which help market the tests… bring you back to more tests.
BofA <a target="_blank" href="https://www.benzinga.com/quote/NEO/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a> on NeoGenomics given near-term headwinds and more limited upside versus its prior trajectory.
<h2 class="wp-block-heading">Quest Diagnostics</h2>
Quest Diagnostics is showing trends toward AI in precision medicine with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Haystack and PathAI Quest</a>.
While not traditionally considered a &#8220;leader&#8221; in AI/precision medicine, Quest Diagnostics has shown progress toward becoming a company to watch.
At DGX&#8217;s 2025 Investor Day, management discussed innovations in lab diagnostics, including the adoption of AI and automation. Given Quest Diagnostics&#8217; strong, steady performance and lower exposure to macro/policy overhangs, the analyst <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a>.
<h2 class="wp-block-heading">LabCorp</h2>
LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) aims to be a notable player in AI precision medicine. Although LabCorp is known as a traditional reference lab, with trends toward AI and precision medicine, LH has shown signs of <a target="_blank" href="https://www.benzinga.com/25/02/43539754/labcorp-reports-q4-earnings-beat-and-expects-strong-2025-growth-analyst-reiterates-outperform-on-stable-2025-outlook" rel="noreferrer noopener">jumping on the bandwagon</a>.
While LabCorp already offers NGS tests, there appears to be a clear trend and focus towards advancing its AI/precision medicine portfolio.
BofA <a target="_blank" href="https://www.benzinga.com/quote/LH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on LabCorp, given strong and steady performance and lower exposure to macro/policy overhangs.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Biotech

News

Health Care

Analyst Ratings

General

EXAS

Laboratory Corporation Of America Holdings

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

<a href="https://breakingdefense.com/2025/06/boeing-hires-former-northrop-exec-to-lead-air-force-one-program/">https://breakingdefense.com/2025/06/boeing-hires-former-northrop-exec-to-lead-air-force-one-program/</a>

'Boeing Hires Former Northrop Exec To Lead Air Force One Program'- Breaking Defense

Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock is trending on Wednesday after hitting all-time highs. Here&#8217;s a look at what you <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46084249/robinhood-markets-hood-stock-hits-a-new-all-time-high-whats-going-on">need to know</a>.
What To Know: Robinhood is expected to provide an update on June trading metrics this week, according to the company&#8217;s investor relations site. Robinhood also held its annual shareholder meeting on Wednesday. 
The Robinhood website says the company is anticipated to release&nbsp;&#8220;month-to-date trading color&#8221; for June after the market close on Thursday. Earlier this month, the company provided early color on May operating data ahead of a presentation at the Piper Sandler Global Exchange &amp; Trading conference.
As of the end of May, Robinhood said it had 25.9 million funded accounts and $255 billion in platform assets, up 89% year-over-year. The company reported $3.5 billion in net deposits for the month and $59.1 billion in total deposits over the past year.
Equity trading volumes rose 108% to $180.5 billion, while options contracts increased 36% to 179.8 million. Crypto volumes were also up 65% to $11.7 billion last month.
Robinhood may also be getting a boost in recent trading sessions after a director disclosed the purchase of nearly $2 million in common stock, the first insider buy reported in several years, according to Benzinga&#8217;s Insider Trades <a href="https://www.benzinga.com/quote/HOOD/insider-trades">data</a>. 
Recent analyst updates suggest analysts are turning more bullish with Mizuho maintaining an Outperform rating and raising its price target to $80 last week. Goldman Sachs also reiterated a Buy rating earlier this month and raised its target to $82 and Deutsche Bank lifted its target to $85.
Robinhood CEO Vlad Tenev said on CNBC this week that retail investor activity has remained strong despite rising <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46097909/robinhood-ceo-highlights-retail-investor-interest-in-nvidia-tesla-despite-middle-east-tensions-barely-a-blip">geopolitical tensions in the Middle East</a>. He noted that while such events once triggered volatile overnight moves, current investor sentiment appears largely unaffected, with continued focus on growth stocks like Nvidia and Tesla, as well as crypto assets.
HOOD Price Action: Robinhood shares were up 0.44% at $82.37 at the time of writing. The stock hit another all-time high of $85.55 earlier in Wednesday&#8217;s trading session, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46101160/why-is-nektar-therapeutics-stock-trading-higher-on-wednesday">Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?</a></li>
</ul>
Image: NRSPro/Shutterstock.

Movers

HOOD

What's Going On With Robinhood Stock Today?

Calamos Investments is refreshing the <a href="https://www.benzinga.com/etfs">income ETF turf</a> with the launch of Calamos Autocallable Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAIE#NYSE">CAIE</a>) on Wednesday. 
This fund aims to make one of Wall Street&#8217;s more esoteric structured products a liquid, accessible solution for investors.
In its essence, CAIE invests in a ladder portfolio of autocallable notes, which are structured securities that offer frequent coupons and can return principal, provided the underlying equity index does not drop below a specified barrier. 
The ETF aims for high, predictable monthly income and thus serve as a substitute for individuals wanting yields greater than those of regular fixed-income vehicles.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/46100785/not-enough-believers-faith-based-etf-folds-amid-industry-purge">Not Enough Believers: Faith-Based ETF Folds Amid Industry Purge</a>
The underlying index is the MerQube US Large-Cap Vol Advantage Index, and the auto callables will be designed to mature in five years, with a -40% coupon and maturity barrier. If the reference index experiences a gain, the notes will be automatically callable after a one-year non-call period. The fund will ladder more than 52 such notes, weekly staggered, to assist in mitigating timing risk and smoothing income.
Backing the fund is a heavy-hitting roster: J.P. Morgan is the lead swap counterparty, MerQube supplies the index, and Calamos oversees the portfolio. The ETF will have a 0.74% expense ratio and feature daily liquidity and tax-favored distributions, an unusual combination for such a strategy.
This action connects to a surging demand for defined income. 
Autocallable structured notes alone were issued for more than $104 billion in 2024, comprising over two-thirds of the structured products market. 
Derivative income funds, such as trendy covered-call ETFs, have seen net inflows totaling $39 billion, bringing the total assets under management to $114 billion.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46098656/nvidia-amazon-tesla-among-tech-stocks-hedge-funds-are-piling-into-heres-how-etfs-like-ivv-spy-voo-are-riding-the-wave">Nvidia, Amazon, Tesla Among Tech Stocks Hedge Funds Are Piling Into — Here&#8217;s How ETFs Like IVV, SPY, VOO Are Riding The Wave</a></li>
</ul>
Image: Shutterstock

New ETFs

CAIE

Calamos Unveils Callable-Note ETF For Predictable Payouts

<a href="https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter">https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter</a>

BRKR

ILMN

QTRX

'NIH halts grant terminations 'effective immediately,' email says'- Stat News

Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $226.6, with a high estimate of $265.00 and a low estimate of $178.00. This current average has increased by 1.71% from the previous average price target of $222.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878092_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Honeywell Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$226.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$258.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$226.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$243.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$229.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$205.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$178.00</td>
<td>$205.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Honeywell Intl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Honeywell Intl compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Honeywell Intl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Honeywell Intl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Honeywell Intl analyst ratings.</a>
<h2>Delving into Honeywell Intl's Background</h2>
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.
<h3>Unraveling the Financial Story of Honeywell Intl</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Honeywell Intl's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.87% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.75%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Honeywell Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Honeywell Intl's ROA stands out, surpassing industry averages. With an impressive ROA of 1.93%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.88, Honeywell Intl adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Assess Honeywell Intl: What You Need To Know

Across the recent three months, 17 analysts have shared their insights on Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $114.65, a high estimate of $145.00, and a low estimate of $85.00. This current average represents a 4.85% decrease from the previous average price target of $120.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878071_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Shake Shack's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$134.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Trainor</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$131.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$97.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$127.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Shake Shack. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Shake Shack compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Shake Shack's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Shake Shack's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHAK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Shake Shack analyst ratings.</a>
<h2>About Shake Shack</h2>
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
<h3>Unraveling the Financial Story of Shake Shack</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Shake Shack's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.46%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Shake Shack's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 1.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Shake Shack's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.9%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Shake Shack's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.25%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Shake Shack's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.74.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHAK

A Glimpse Into The Expert Outlook On Shake Shack Through 17 Analysts

TE Connectivity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) short percent of float has fallen 15.32% since its last report. The company recently reported that it has 4.95 million shares sold short, which is 1.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>TE Connectivity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750878060_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TE Connectivity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing TE Connectivity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, TE Connectivity's peer group average for short interest as a percentage of float is 3.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About TE Connectivity?

Rambus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NYSE">RMBS</a>) short percent of float has fallen 10.36% since its last report. The company recently reported that it has 3.41 million shares sold short, which is 4.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Rambus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750878055_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Rambus has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Rambus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Rambus's peer group average for short interest as a percentage of float is 9.76%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

RMBS

How Is The Market Feeling About Rambus?

In the current session, Globus Medical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) is trading at $58.35, after a 0.53% decrease. Over the past month, the stock fell by 1.45%, and in the past year, by 15.25%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750878053_0.png" alt="Past Year Chart" />

<h3>Globus Medical P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 54.65 in the Health Care Equipment &amp; Supplies industry, Globus Medical Inc. has a lower P/E ratio of 43.78. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750878053_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

GMED

Price Over Earnings Overview: Globus Medical

Dillard's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>) short percent of float has risen 7.57% since its last report. The company recently reported that it has 932 thousand shares sold short, which is 34.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Dillard's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750878050_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dillard's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dillard's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Dillard's's peer group average for short interest as a percentage of float is 9.54%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Dillard's?

Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $22.2, a high estimate of $24.00, and a low estimate of $20.00. The current average, unchanged from the previous average price target, holds steady. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878048_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Kennametal's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kennametal. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kennametal compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Kennametal's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Kennametal's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kennametal analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Kennametal Better</h2>
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
<h3>Financial Milestones: Kennametal's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Kennametal's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -5.7%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Kennametal's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 6.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kennametal's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.56%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Kennametal's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.28%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Kennametal's debt-to-equity ratio stands notably higher than the industry average, reaching 0.53. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Kennametal: 5 Analysts Share Their Views

In the latest quarter, 33 analysts provided ratings for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">6</td>
<td align="right">15</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $201.33, a high estimate of $250.00, and a low estimate of $130.00. This current average has increased by 10.52% from the previous average price target of $182.16. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878039_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Oracle among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$196.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$221.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$195.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$240.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$215.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$246.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$200.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Oracle. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Oracle compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Oracle's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Oracle's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oracle analyst ratings.</a>
<h2>Discovering Oracle: A Closer Look</h2>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
<h3>Unraveling the Financial Story of Oracle</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Oracle's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.31% as of 31 May, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Oracle's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.55% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Oracle's ROE excels beyond industry benchmarks, reaching 18.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Oracle's ROA stands out, surpassing industry averages. With an impressive ROA of 2.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Oracle's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.09, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

A Glimpse Into The Expert Outlook On Oracle Through 33 Analysts

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Cheesecake Factory, presenting an average target of $50.67, a high estimate of $62.00, and a low estimate of $40.00. A 0.65% drop is evident in the current average compared to the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878028_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cheesecake Factory. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>John Glass</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$62.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cheesecake Factory. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Cheesecake Factory compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Cheesecake Factory's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cheesecake Factory's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CAKE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cheesecake Factory analyst ratings.</a>
<h2>About Cheesecake Factory</h2>
Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, other FRC, and Flower Child. Majority of the company's revenue comes from The Cheesecake Factory restaurants segment.
<h3>Cheesecake Factory's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Cheesecake Factory's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.04% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Cheesecake Factory's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.55%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Cheesecake Factory's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.42% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cheesecake Factory's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Cheesecake Factory's debt-to-equity ratio surpasses industry norms, standing at 6.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAKE

The Analyst Verdict: Cheesecake Factory In The Eyes Of 9 Experts

Throughout the last three months, 22 analysts have evaluated Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Texas Instruments and provided 12-month price targets. The average target is $183.91, accompanied by a high estimate of $225.00 and a low estimate of $125.00. A 8.42% drop is evident in the current average compared to the previous average price target of $200.81. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878014_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Texas Instruments among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$171.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kevin Garrigan</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$216.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$125.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Texas Instruments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Texas Instruments compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Texas Instruments's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Texas Instruments's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TXN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Texas Instruments analyst ratings.</a>
<h2>Discovering Texas Instruments: A Closer Look</h2>
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
<h3>Financial Insights: Texas Instruments</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Texas Instruments showcased positive performance, achieving a revenue growth rate of 11.14% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Texas Instruments's net margin is impressive, surpassing industry averages. With a net margin of 28.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Texas Instruments's ROE stands out, surpassing industry averages. With an impressive ROE of 7.08%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Texas Instruments's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Texas Instruments's debt-to-equity ratio surpasses industry norms, standing at 0.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

22 Analysts Have This To Say About Texas Instruments

Zohran Mamdani is expected to win the New York City Democratic Primary in a <a href="https://www.benzinga.com/news/politics/25/06/46087359/zohran-mamdani-leads-nyc-mayoral-primary-andrew-cuomo-concedes-race">surprising turn of events, </a>defeating former New York Governor Andrew Cuomo.
While the win secures Mamdani a spot on the general election ballot, he still faces a tough road in November's mayoral race.
What Happened: On Tuesday night, Cuomo—backed by several billionaires during the race—quickly congratulated Mamdani on his primary victory. But he also made it clear he hasn't ruled out an independent run in the November election. 

"I said he won the primary election," Cuomo <a href="https://www.nytimes.com/2025/06/25/nyregion/nyc-mayor-election-november.html">told </a>the New York Times. "I said I wanted to look at the numbers and the ranked-choice voting to decide about what to do in the future, because I'm also on an independent line. And that's the decision, that's what I was saying."
With no candidate receiving a 50% majority on Tuesday night, voters&#8217; second-place votes will be counted in a process that eliminates candidates and continues until one remains.
Cuomo's defeat came as a surprise to many. The former governor resigned four years ago amid sexual harassment allegations, which he denied. Backed by billionaires, Cuomo also aligned more closely with the traditional Democratic establishment than Mamdani, a democratic socialist.
Mamdani, 33, has sparked widespread debate with a platform that includes freezing rent, raising taxes on the wealthy, free city bus service, universal child care, and city-owned grocery stores.
Those policies have proven unpopular with the wealthy city residents and could see money poured towards candidates to defeat Mamdani in the November election.
Read Also: <a href="https://www.benzinga.com/news/legal/25/03/44094049/cuomos-mayoral-bid-shakes-up-nyc-race-drawing-major-power-brokers-and-critics-alike">Cuomo&#8217;s Mayoral Bid Shakes Up NYC Race, Drawing Major Power Brokers And Critics Alike</a>
What Happens Next: Mamdani's potential win on Tuesday is no guarantee that he will win in November. Regardless of whether Cuomo jumps in as an Independent, Mamdani will face off against incumbent mayor Eric Adams.
Adams is a Democrat who has been at odds with his party and is choosing to run in the November election as an Independent.
Some Democrats are hoping that Cuomo doesn't run in the general election, as his inclusion could split votes between Cuomo and Adams and secure a path for Mamdani to win the election. The large majority of Democratic voters, who outnumber the Republicans six-to-one, according to the New York Times, could split the vote between multiple candidates.
Another potential option could be a third-party run by someone like Andrew Yang, who previously ran in the New York City mayoral race in 2021 and ran for president in the 2020 election.
Yang established the Forward Party and, according to The Hill, reached out to billionaire Elon Musk as recently as this month to collaborate on a third party.
"We have been of the opinion that America needed a new political party for a number of years," Yang told <a href="https://www.politico.com/news/magazine/2025/06/07/elon-musk-third-party-andrew-yang-interview-00392288">Politico </a>in an interview.
Yang reached out to Musk at a time when Musk was feuding with President Donald Trump and even polled his X followers to see if a third party that represents those who identify in the middle politically should be launched. Over 5.6 million people voted in the <a href="https://x.com/elonmusk/status/1930685402631053403" target="_blank" rel="noopener">poll,</a><a href="https://x.com/elonmusk/status/1930685402631053403"> </a>with 80.4% saying yes, although not all the votes were likely from eligible American voters.
Yang has been supportive of Musk and the potential of a third party, which comes after Musk spent hundreds of millions to help support Trump in the 2024 presidential election.
"I want to work with people that recognize that America's political system has gone from dysfunctional to polarizing to even worse. And at this point, the fastest growing political movement in the United States is independents."
Yang highlighted that Musk has supported candidates that are both Democratic and Republican in the past and like other voters who supported Trump and the "Make America Great Again" movement, could be looking for alternatives going forward.
On Wednesday, Yang <a href="https://x.com/AndrewYang/status/1937858506704539894">tweeted </a>that &#8220;it&#8217;s a new day,&#8221; while sharing several posts about the NYC mayoral race.
While Yang or Cuomo will not necessarily run in the New York City mayoral race, a broader field of independent candidates could split the vote, making this one of the most consequential tests of whether a third party can win a major race.
Current odds on prediction market <a href="https://polymarket.com/event/new-york-city-mayoral-election">Polymarket </a>show Mamdani as the favorite to win the November election at 73.1%, followed by Adams at 22.0%. Cuomo is listed with a current 2.9% chance, but that comes without him declaring an Independent run. Yang is listed with less than a 1% chance of winning, without publicly entering the race.
Another Polymarket prediction market is for whether Cuomo will run as a non-Democrat in the general election, with yes getting 34% of the vote.
On <a href="https://kalshi.com/?live=new-york-city-mayor-election">Kalshi</a>, Mamdani is the favorite at 73%, followed by Adams and 24% and Cuomo at 5%. Yang is not currently listed.
Mamdani's primary win could impact stocks with a heavy presence in New York. Here are several movers <a href="https://x.com/SaraEisen/status/1937905974960062625">highlighted </a>by CNBC's Sara Eisen.
Flagstar Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) is down 5% to $10.63 on Wednesday.
SL Green Realty Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) is down 5% to $58.63 on Wednesday.
Vornado Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) is down 6% to $36.23 on Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45807476/mark-cuban-check-marks-elon-musks-idea-of-a-new-political-party-that-represents-the-middle">Mark Cuban Check Marks Elon Musk&#8217;s Idea Of A New Political Party That Represents &#8216;The Middle&#8217;</a></li>
</ul>
Photo: Ron Adar / Shutterstock.com

Politics

Democratic Party Implodes As MAGA Revolts — Can Musk, Yang Build Third Party?

<a href="https://x.com/BitcoinMagazine/status/1937944775820468637">https://x.com/BitcoinMagazine/status/1937944775820468637</a>

Bitcoin Magazine Posts On X "White House Deputy Director said there is an 'accumulation plan' for the US to buy more Bitcoin"

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) on Wednesday announced<a href="https://www.globenewswire.com/news-release/2025/06/25/3104985/0/en/Biogen-to-Advance-Investigational-Spinal-Muscular-Atrophy-Asset-to-Registrational-Studies-Based-on-Positive-Interim-Phase-1-Results.html"> in</a> a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">spinal muscular atrophy (SMA)</a>.
Biogen licensed the global development, manufacturing and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>). Salanersen was discovered by Ionis.
Leveraging the same mechanism of action as Spinraza (nusinersen) but designed to achieve greater potency, salanersen can achieve high efficacy and enable once-a-year dose.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/06/45949485/supernus-pharma-acquires-maker-of-postpartum-depression-drug-zurzuvae-in-795-million-deal" rel="noreferrer noopener">Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal</a>
An interim analysis of the phase one study in participants with SMA who were previously treated with Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) gene therapy, Zolgensma (onasemnogene abeparvovec), was conducted to inform the decision on whether to move salanersen forward <a href="https://www.benzinga.com/pressreleases/25/06/g46091748/biogen-to-advance-investigational-spinal-muscular-atrophy-asset-to-registrational-studies-based-on" target="_blank" rel="noreferrer noopener">into registrational studies</a>.
Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament.
Exploratory clinical outcome data show clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over one year.
Interim results are from part B (n=24) in individuals who received either 40 mg or 80 mg salanersen once a year.
In participants with elevated baseline concentrations of neurofilament light chain (NfL), indicating ongoing neurodegeneration, initiation of salanersen led to mean reductions in NfL of 70% at six months, which were sustained through the one-year dosing interval.
Exploratory clinical outcome data were evaluated for the subgroup of participants with at least one year of follow-up during the interim analysis (n=8 participants aged 2-12 who received 40 mg of salanersen). Half (four out of eight) of these participants achieved new WHO motor milestones they could not previously achieve on their own or required assistance, such as walking, crawling, standing or sitting.
Furthermore, these participants experienced clinically meaningful improvements in motor function from baseline to one year, including a 3.3-point (SD 4.46) mean improvement from baseline on the Hammersmith Functional Motor Scale – Expanded (HFMSE) and a 5.3 point (SD 4.75) improvement on the Revised Upper Limb Module (RULM).
Biogen is currently engaging with global health authorities regarding the design of the phase 3 studies.
Earlier in June, Biogen initiated dosing in the BRAVE phase 3 study to evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between <a href="https://www.benzinga.com/pressreleases/25/06/g45992415/biogen-initiates-phase-3-pediatric-study-of-omaveloxolone-for-the-treatment-of-friedreich-ataxia" target="_blank" rel="noreferrer noopener">the ages of 2 to &lt;16</a>.
Both non-ambulatory and ambulatory participants may qualify for the study.
Currently, omaveloxolone is commercialized under the brand name Skyclarys in over 40 countries, including the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.
BIIB Price Action: Biogen stock is up 0.58% at $127.04 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46097512/robotaxi-roll-out-tesla-uber-and-waymo-take-diverging-roads-to-autonomy" target="_blank" rel="noreferrer noopener">Robotaxi Roll Out: Tesla, Uber And Waymo Take Diverging Roads To Autonomy</a></li>
</ul>
Photo: New Africa via Shutterstock

BIIB

IONS

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma

WIIM

ONDS

ONDS stock has given up its prior gain. Ondas Holdings shares were trading higher after announcing a partnership with Detroit Manufacturing Systems to boost U.S. drone production.

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">long-term treatment</a>.
While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are increasingly used, poor persistence rates threaten the clinical and economic benefits of these medications.
Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is the main input in Ozempic and Wegovy, and tirzepatide is a key ingredient in Eli Lilly &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly</a>
GLP-1 agonists have been linked to 10% to 20% weight loss in clinical trials, with some studies also showing reduced cardiovascular events in individuals without diabetes.
Yet, despite these benefits, long-term adherence remains a major hurdle. A 2023 real-world study by Prime Therapeutics found that just 27% of users remained adherent for one year, and only 15% persisted for two years. At three years, only 8.1% of users were still on treatment.
Even the best-performing drug, Wegovy, had a three-year persistence rate of just 14.3%.
The three-year analysis included 5,780 individuals continuously enrolled in a health plan after initiating GLP-1 treatment for obesity.
The group had a mean age of 46.7 years, and nearly 80% were women. Persistence rates varied widely by medication, from 14.3% with weekly semaglutide (Wegovy) to 2.5% with daily liraglutide (Victoza).
Over three years, only 12.5% of users met the standard for adherence based on medication possession, and more than one-third switched to a different GLP-1 therapy.
However, more recent <a target="_blank" href="https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years" rel="noreferrer noopener">data</a> suggests that persistence may be improving. In a separate year-over-year analysis involving 23,025 individuals initiating high-potency GLP-1s—Wegovy and Zepbound—one-year persistence rose from 33.2% in 2021 to 62.7% in 2024.
Tirzepatide (Zepbound), introduced in late 2023, had one-year persistence rates of over 62% in both 2023 and 2024.
This trend toward better short-term adherence is attributed to reduced supply shortages, improved dose escalation strategies, better side-effect management, and support programs.
Nonetheless, experts <a target="_blank" href="https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence" rel="noreferrer noopener">caution</a> that poor long-term persistence among early adopters signals potential investment risk and limits the therapies' full clinical impact.
Further research is needed to understand why so many users discontinue treatment and whether newer approaches can sustain adherence over the long term.
Price Action: LLY stock is up 1.92% at $792.37, and NVO stock is down 5.03% at $67.17 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows

Press Releases

B2Gold Completes Phase 2 Expansion of Fekola Solar Plant in Mali

B2Gold Announces Updated Mineral Reserve Life of Mine Plan for the Goose Project; Commencing a Study to Expand Mill Throughput at the Goose Project; B2Gold Confirms Construction and Mine Development Cash Expenditure Estimate of C$1,540 million

B2Gold Announces TSX Approval for Normal Course Issuer Bid

Offerings

Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares

B2Gold First Quarter 2025 Financial Results – Conference Call Details

Earnings

Dividends

B2Gold Reports Q1 2025 Results

With Gold Recent Record Highs, New Canadian Producer on its way; ESGold Corp. (CSE: ESAU ) (OTCQB: ESAUF)

B2Gold Releases its Ninth Annual Responsible Mining Report and its Fourth Annual Climate Strategy Report

B2Gold 2025 Annual General and Special Meeting Details and Voting Reminder

B2Gold Announces Voting Results from its 2025 Annual General and Special Meeting

CSE:ESAU

ESAUF

SNWGF

TSX:ABX

TSX:BTO

TSX:K

TSXV:SGD

CIBC

Jefferies

RBC Capital

월요일(21일) 금 가격이 사상 최고치로 급등했다. 금은 월요일 오전 11시 20분(동부표준시 기준) 온스당 2.5% 상승한 3,410달러로 상승했다. 이는 미국 금융자산에 대한 불신과 인플레이션 우려로 인해 <a href="https://www.benzinga.com/topic/donald-trump" target="_blank" rel="noopener">2010년대 초</a> 글로벌 부채 위기 이후 볼 수 없었던 안전자산으로의 도피가 이어지는 것을 의미한다.
3월 초부터 SPDR Gold Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>)가 추적하는 금 가격은 19.4%라는 놀라운 상승률을 기록하며 2011년 8월 이후 가장 강력한 2개월 랠리를 이어가고 있다.
거시 경제 불안정성, 정치적 마찰, 달러와 미국 국채에 대한 투자자들의 회의론이 &#8216;퍼펙트 스톰&#8217;을 일으키며 금 상승세를 지지했다.
<h3 class="wp-block-heading">금 가격 급등의 배경은?</h3>
금의 극적인 상승 근원은 펀더멘털, 구조적, 행동적 동인의 강력한 조합에 있다.
한때 안전한 피난처였던 미국 달러와 장기 국채는 최근 몇 주 동안 도널드 트럼프 대통령의 관세 공세와 제롬 파월 연준 의장과의 불화가 심화되면서 정치적 개입에 대한 우려가 커지고 미국 기관에 대한 신뢰가 약화되는 가운데 압력을 받고 있다.
이러한 상황에서 중립적이고 오랜 기간 검증된 가치 저장 수단이라는 금의 명성은 안정성을 추구하는 자본을 끌어들이고 있다.
그 결과 전통적인 헤지 수단이 흔들리는 중이다. 그러나 금은 권력자의 실수에 영향을 받지 않고 수 세기에 걸친 가치 저장 수단으로서의 지위를 바탕으로 하기 때문에 거시적 불확실성 증가로부터 피난처를 찾는 자본의 피난처로 부상했다.
<h3 class="wp-block-heading">금 ETF에 대한 대규모 자금 유입, 강력한 투자 수요 의미</h3>
금에 대한 투자자들의 열망은 트럼프가 백악관으로 공식 복귀한 1월 중순 이후 금으로 뒷받침되는 상장지수펀드(ETF)로의 대규모 자금 유입을 통해 분명히 확인할 수 있다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>ETF</th>
<th>유입액 (1월 중순 ~ 4월 중순)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>)</td>
<td>$83억 5천만</td>
</tr>
<tr>
<td>iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>)</td>
<td>$35억</td>
</tr>
<tr>
<td>SPDR Gold MiniShares Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLDM#NYSE">GLDM</a>)</td>
<td>$24억 6천만</td>
</tr>
<tr>
<td>ProShares Ultra Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGL#NYSE">UGL</a>)</td>
<td>$1억 1,700만</td>
</tr>
<tr>
<td>Goldman Sachs Physical Gold ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAAU#NYSE">AAAU</a>)</td>
<td>$3억 490만</td>
</tr>
</tbody>
</table>
</figure>
이러한 대규모 유입 흐름은 광범위한 기관 및 소매 수요를 나타낸다. 골드만삭스 애널리스트 리나 토마스는 이번 랠리가 단기 투기 세력에 의해 주도되고 있지 않다고 말했다.
토마스는 "데이터에 따르면 투기적 흐름이 크게 회복되지 않은 상태에서 이러한 움직임이 발생했다&#8221;고 했다.
"COMEX 투기 포지션이 여전히 온건한 것으로 추정되는 가운데, 이번 랠리는 구조적으로 뒷받침되고 있으며 급격한 단기 청산 위험에 덜 노출된 것으로 보인다. 따라서 현재 수준을 전술적으로 매력적인 진입점으로 보고 있으며, 이는 연말 전망치인 3,700달러에 대한 상승 리스크를 강화한다고 생각한다.&#8221;
야데니 리서치의 대표인 에드 야데니는 현재의 금 모멘텀이 1년 전의 자신의 주장을 입증하고 있다고 말했다.
&#8220;2024년 2월 말 온스당 2,000달러를 돌파한 이후 금에 대해 강세를 보였다. 올해 말까지 4,000달러 목표가 점점 더 현실적으로 보인다. 그렇게 된다면 2026년 말에는 5,000달러가 목표가 될 것이다.&#8221;
더 골드 불리언 컴퍼니(The Gold Bullion Company)의 릭 칸다(Rick Kanda)는 이렇게 말했다. "이러한 상황은 많은 자산에 위기로 다가올 수 있지만, 금에 있어서는 완벽한 결과다. 미국 주식시장에서 수조 달러의 손실이 발생하고 투자자들이 주식이나 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 같은 위험 자산보다는 안전자산을 찾아 실물 금으로 기울면서 인플레이션에 대한 우려가 여전히 높다.&#8221;
<h3 class="wp-block-heading">금광업체들, 모멘텀 되찾다</h3>
이러한 금 랠리는 2024년 대부분의 기간 동안 실물 금괴가 부진했던 금광업체들도 끌어올리고 있다. 반에크는 월요일에 "금은 금 상장지수펀드에 대한 새로운 자금 유입과 글로벌 중앙은행의 지속적인 수요 강세에 힘입어 온스당 3,000달러를 넘어 사상 최고치까지 치솟았다&#8221;고 했다.
"동시에 금광업체는 금 가격에 대한 레버리지를 회복하기 시작하여 올해 지금까지 가장 실적이 좋은 주식으로 부상하고 있다."
VanEck Gold Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)는 연초 대비 52% 가까이 상승하며 2007년 펀드 출범 이후 가장 높은 연간 상승률을 기록했다.
금의 강력한 랠리에 대응하여 월요일 뱅크오브아메리카는 북미 금 및 은 관련 기업에 대한 목표주가를 올렸다.
이는 귀금속 부문의 1분기 실적 시즌을 앞두고 나온 조치로, 4월 23일에는 뉴몬트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), 4월 24일에는 애그니코 이글 마인스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>)가 실적을 발표할 예정이다.
주요 종목의 새로운 목표주가는 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>종목</th>
<th>새로운 목표주가</th>
<th>이전 목표주가</th>
</tr>
</thead>
<tbody>
<tr>
<td>애그니코 이글 마인스</td>
<td>$159</td>
<td>$142</td>
</tr>
<tr>
<td>배릭 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>)</td>
<td>$23</td>
<td>$19.50</td>
</tr>
<tr>
<td>킨로스 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>)</td>
<td>$17.50</td>
<td>$15</td>
</tr>
<tr>
<td>뉴몬트</td>
<td>$70</td>
<td>$60</td>
</tr>
<tr>
<td>B2골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTG#NYSE">BTG</a>)</td>
<td>$3.10</td>
<td>$2.75</td>
</tr>
<tr>
<td>센테라 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGAU#NYSE">CGAU</a>)</td>
<td>$6.50</td>
<td>$5.50</td>
</tr>
<tr>
<td>엘도라도 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGO#NYSE">EGO</a>)</td>
<td>$19.50</td>
<td>$17.25</td>
</tr>
<tr>
<td>아이엠골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>)</td>
<td>$9.25</td>
<td>$7.75</td>
</tr>
<tr>
<td>SSR 마이닝 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>)</td>
<td>$9.75</td>
<td>$8.50</td>
</tr>
<tr>
<td>알라모스 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>)</td>
<td>$35</td>
<td>$30.50</td>
</tr>
<tr>
<td>뉴 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGD#NYSE">NGD</a>)</td>
<td>$4.55</td>
<td>$4.10</td>
</tr>
<tr>
<td>팬 아메리칸 실버 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NASDAQ">PAAS</a>)</td>
<td>$32</td>
<td>$27</td>
</tr>
<tr>
<td>프랑코 네바다 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>)</td>
<td>$195</td>
<td>$165</td>
</tr>
<tr>
<td>로얄 골드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>)</td>
<td>$183</td>
<td>$164</td>
</tr>
<tr>
<td>트리플 플래그 프레셔스 메탈스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#NYSE">TFPM</a>)</td>
<td>$27</td>
<td>$24</td>
</tr>
<tr>
<td>휘턴 프레셔스 메탈스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>)</td>
<td>$100</td>
<td>$86</td>
</tr>
</tbody>
</table>
</figure>
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금 가격의 강력한 상승세가 계속되고 있다. 목요일 금이 새로운 최고가를 경신한 것은 투자자들이 증가하는 무역 긴장과 경제적 불확실성으로부터 포트폴리오를 보호하려고 서두른 결과이다.
 SPDR 골드 트러스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>)가 추적하는 금 현물 가격은 동부 표준시 기준 오후 1시 55분에 온스당 2,979.76달러로 거래되었으며, 이는 1.6% 상승한 것으로, 세 번째 연속 상승세를 기록했다. 금속은 2025년까지 14% 급등하여 모든 주요 자산 클래스보다 높은 상승률을 보였다.
SPDR S&amp;P 500 ETF 트러스트(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)로 추적되는 S&amp;P 500 지수는 5.9% 하락했고, 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)는 12% 하락했으며, 미국 달러 지수도 연초 대비 4% 하락했다.
<h1 class="wp-block-heading">금 가격 상승의 원인은?</h1>
금 가격 상승은 경제적 및 지정학적 위험이 복합적으로 작용한 결과이다. 도널드 트럼프 대통령의 행정부는 높은 관세로 여러 국가들을 위협함으로써 글로벌 무역 전쟁에 대한 두려움을 다시 불러일으켰다.
한편, 경제적 약화의 신호가 더욱 뚜렷해지고 있다. 애틀랜타 연방준비은행의 GDP나우 모델은 2025년 1분기 미국 경제가 2.4% 축소될 것으로 전망하고 있으며, JP모건은 올해 경기 침체 확률을 40%로 상향 조정했다.
&#8220;최근 금 가격 상승을 주도하는 대규모의 알려지지 않은 플레이어가 있다,&#8221;고 메탈스 데일리(Metals Daily)의 CEO인 로스 노먼(Ross Norman)이 말했다. 이는 금속이 정상적인 거래 패턴을 무시하고 수익률 채권과 통화 변동에도 불구하고 상승하고 있는 이유를 설명할 수 있다.
&#8220;트럼프 대통령이 시작한 무역 전쟁이 악화됨에 따라 금이 현재 가장 잘 나가는 자산 중 하나인 이유는 분명하다,&#8221;고 베테랑 시장 전략가 에드 야데니(Ed Yardeni)가 말했다.
<h1 class="wp-block-heading">금 가격의 향후 전망은?</h1>
위험 회피가 감정을 지배함에 따라 분석가들은 금 가격 전망을 상향 조정하고 있다. UBS 투자은행의 조니 테베스(Joni Teves)는 CNBC의 &#8220;스쿼크 박스(Squawk Box)&#8221;에서 &#8220;지정학적 환경, 특히 관세로 인한 위험 회피가 여전히 포트폴리오에 금을 추가하는 데 유리하게 작용할 것&#8221;이라고 말했다.
UBS는 금 가격이 올해 말까지 온스당 3,100달러에 이를 것으로 예상하고 있다.
맥쿼리 그룹의 애널리스트들은 더욱 낙관적인 전망을 내놓으며, 금 가격이 3분기까지 3,500달러에 이를 것으로 예상하고 있다.
&#8220;우리는 지금까지 금 가격의 강세와 앞으로도 계속될 것이라는 우리의 예상이 주로 투자자들과 공식 기관들이 신용 위험이나 상대방 위험이 없는 금에 대해 지불할 용의가 더 높아진 것에 의해 주도되었다고 본다,&#8221;라고 이 그룹이 작성했다.
<h1 class="wp-block-heading">금 가격 상승에 따른 광산 주식 상승</h1>
금 가격 상승은 광산 주식에 새로운 활력을 불어넣었지만, 많은 주식들이 여전히 과거의 최고가에 비해 낮은 수준다.
VanEck Gold Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)는 3.13% 상승 마감했지만 여전히 2011년 최고가보다 35% 낮은 수준에서 거래되고 있다. VanEck Junior Gold Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDXJ#NYSE">GDXJ</a>)도 3.48% 상승했지만 여전히 2010년 기록보다 70% 낮은 수준이다.
개별 주식 중에서는 뉴몬트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)가 목요일 4.63% 상승 마감했고, B2골드 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTG#NYSE">BTG</a>)은 5.07% 상승했으며, 킨로스 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>)는 2.43% 상승 마감했다. 프랑코-네바다(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>)는 2.29% 상승, 배릭 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>)는 2.13% 상승 마감했다.
 
지금 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44304426/from-magnificent-7-to-maleficent-7-goldman-sachs-slashes-year-end-sp-500-target">‘매그니피센트 7&#8217;에서 ‘말레피센트 7&#8217;로, 골드만삭스가 연말 S&amp;P 500 목표를 하향 조정</a></li>
</ul>
사진: Shutterstock


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

B2Gold

뉴스

에 대한 최신 뉴스 B2Gold (AMEX:BTG) 주식

화요일, 4월 22, 2025

목요일, 3월 13, 2025

뉴스

파트너 / 기고자

벤징가 글로벌